2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a

Generic Name: 2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₃₉H_₄₈N_₄O_₄

CAS Number: 149402-51-7

Unique Ingredient Identifier: DOB7Y3RSX0

Background: 2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a is under investigation in clinical trial NCT01668823 (Photodynamic Therapy in Treating Patients With Lung Cancer).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer

Phase 1

Completed

Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Recurrent Basal Cell Carcinoma of the Lip
Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
Recurrent Lymphoepithelioma of the Nasopharynx
Recurrent Lymphoepithelioma of the Oropharynx
Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity
Recurrent Mucoepidermoid Carcinoma of the Oral Cavity
Recurrent Salivary Gland Cancer

Interventions: Drug: HPPH
Drug: photodynamic therapy
Procedure: conventional surgery

First Posted Date: 2007-05-07

Last Posted Date: 2022-07-25

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 15

Registration Number: NCT00470496

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Precancerous Condition

Interventions: Drug: HPPH

First Posted Date: 2006-01-25

Last Posted Date: 2014-01-03

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 60

Registration Number: NCT00281736

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Photodynamic Therapy With HPPH in Treating Patients With Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

First Posted Date: 2003-06-25

Last Posted Date: 2011-03-07

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT00025571

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors

Phase 1

Completed

Conditions: Esophageal Cancer

First Posted Date: 2003-05-07

Last Posted Date: 2011-03-09

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 11

Registration Number: NCT00060268

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer

Phase 1

Completed

Conditions: Non-melanomatous Skin Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2011-03-07

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 6

Registration Number: NCT00017485

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy